TD Cowen Begins Coverage on TG Therapeutics (NASDAQ:TGTX)

TD Cowen assumed coverage on shares of TG Therapeutics (NASDAQ:TGTX) in a research note issued on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $50.00 price target on the biopharmaceutical company’s stock. TD Cowen’s price objective suggests a potential upside of 98.97% from the stock’s current price.

Other analysts have also recently issued research reports about the company. The Goldman Sachs Group lifted their price target on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. B. Riley lifted their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $49.00 price target on shares of TG Therapeutics in a report on Wednesday, September 18th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.43.

TG Therapeutics Trading Down 2.3 %

Shares of NASDAQ TGTX opened at $25.13 on Tuesday. The business has a fifty day moving average price of $23.44 and a 200 day moving average price of $19.89. TG Therapeutics has a 1-year low of $7.17 and a 1-year high of $26.41. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The stock has a market capitalization of $3.88 billion, a P/E ratio of 109.26 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.08. The firm had revenue of $73.47 million during the quarter, compared to analyst estimates of $65.92 million. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. TG Therapeutics’s revenue was up 357.0% on a year-over-year basis. During the same period last year, the firm posted ($0.34) EPS. Equities research analysts expect that TG Therapeutics will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. NBC Securities Inc. increased its holdings in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares in the last quarter. Blue Trust Inc. raised its position in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 849 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in shares of TG Therapeutics during the 2nd quarter worth about $35,000. ORG Wealth Partners LLC acquired a new stake in shares of TG Therapeutics during the 3rd quarter valued at about $53,000. Finally, Values First Advisors Inc. purchased a new position in shares of TG Therapeutics in the 3rd quarter valued at about $58,000. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.